Oncolytics Biotech® Completes Domicile Change to the United States
Rhea-AI Summary
Oncolytics (Nasdaq: ONCY) completed its domestication from Alberta, Canada to Nevada, United States, effective March 31, 2026.
The change was approved by shareholders on January 15, 2026; the company continued to British Columbia on March 17, 2026, will keep a Calgary office, and made San Diego its new headquarters. Common stock remains on Nasdaq as ONCY; new CUSIP is 68237V 103 and ISIN is US68237V1035. According to the company, the move aims to improve operational efficiency, streamline regulatory structure, and enhance access to U.S. capital markets.
Positive
- Domestication completed on March 31, 2026
- Shareholder approval recorded on January 15, 2026
- New CUSIP 68237V 103 and ISIN US68237V1035
- Headquarters relocated to San Diego; Calgary office retained
Negative
- None.
News Market Reaction – ONCY
In the Apr 1 session, ONCY gained 9.58%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.0% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-03-19 | AACR data update | Positive | +1.9% | New translational and mechanistic pelareorep data with strong response and PFS signals. |
| 2026-03-02 | Trial launch | Positive | -9.7% | Launch of REO 033 randomized Phase 2 colorectal study leveraging favorable prior REO 022 data. |
| 2026-02-24 | Strategy shift | Positive | +6.6% | Prioritizing registrational programs in anal and colorectal cancer and managing spend post-GOBLET. |
| 2026-02-04 | Fast Track status | Positive | +2.5% | FDA Fast Track Designation for pelareorep regimen in 2L KRAS-mutant MSS metastatic colorectal cancer. |
| 2026-01-14 | Leadership hires | Neutral | +5.0% | New EVP Strategy & Operations and Head of Biostatistics with associated equity inducement grants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often drew positive price reactions, though one strong fundamental update coincided with a notable selloff.
Over the last few months, Oncolytics has focused on advancing pelareorep and sharpening its development strategy. In Feb 2026, it refocused on registrational paths in anal and colorectal cancer and later launched the REO 033 randomized Phase 2 colorectal study. FDA Fast Track designation for pelareorep in 2L KRAS‑mutant MSS CRC and new mechanistic data at AACR 2026 reinforced the clinical thesis. Management also strengthened its team with senior hires in strategy and biostatistics. Today’s U.S. domestication follows corporate steps previously flagged in SEC filings.
Key Terms
domestication regulatory
foreign private issuer regulatory
CUSIP financial
ISIN financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States (the “Domestication”) through a series of transactions in which the Company first continued its existence from the Province of Alberta in Canada to the Province of British Columbia in Canada on March 17, 2026. The Company will retain its office in Calgary, while the San Diego office will become the Company’s new headquarters.
The Domestication was approved by the Company’s shareholders at the Special Meeting of Shareholders held on January 15, 2026. The Company completed the Domestication on March 31, 2026, when necessary filings were submitted to, and made effective by, the Nevada Secretary of State. The Company’s common stock will continue to trade on The Nasdaq Stock Market LLC under the ticker symbol “ONCY.” Effective today, the CUSIP number applicable to the Company’s common stock will be 68237V 103, and the ISIN will be US68237V1035.
Today, most of the Company’s investors, management team, and capital markets activity are U.S.-based. We expect this transition to bring several benefits to the Company and its stockholders, including greater operational efficiency, a streamlined regulatory structure, and improved access to U.S. capital markets.
“We are encouraged by the potential benefits that Nevada’s corporate legal environment presents to biotech companies, especially given our focus on operational efficiency across the company,” said Jared Kelly, Chief Executive Officer of Oncolytics. “As we no longer qualified as a “foreign private issuer” under applicable U.S. securities laws, it made sense to overhaul our corporate structure and change Oncolytics’ jurisdiction of incorporation to reflect its status as a U.S. domestic issuer. While our clinical data and regulatory strategy will ultimately give us the best opportunity to create long-term value, we believe our new corporate structure will streamline our ability to execute on our goals.”
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”).
Forward-looking statements contained in this press release include statements regarding the Company’s offices in Calgary, Alberta and San Diego, California; the expected benefits from Oncolytics’ new corporate structure, including the change in the jurisdiction of incorporation of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States; the potential benefits that Nevada’s corporate legal environment presents to biotech companies, such as Oncolytics; beliefs as to the potential, registration, mechanism of action, and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives, and its potential to create long-term value for Oncolytics; expectations around the design, milestones, anticipated timelines, and expected outcomes for current and future studies; and its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic, and other gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
